We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
-2.22%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$5.91M
(+0.55%)
Cap. Flow
+$69.6M
Cap. Flow
% of AUM
6.48%
Top 10 Holdings %
Top 10 Hldgs %
36.46%
Holding
509
New
13
Increased
172
Reduced
270
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$12.7M |
| 2 |
Amazon
AMZN
|
+$9.6M |
| 3 |
Microsoft
MSFT
|
+$7.09M |
| 4 |
Analog Devices
ADI
|
+$4.96M |
| 5 |
Broadcom
AVGO
|
+$4.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Silver Trust
SLV
|
+$7.41M |
| 2 |
ProShares Ultra Gold
UGL
|
+$6.74M |
| 3 |
Arista Networks
ANET
|
+$6.7M |
| 4 |
Gilead Sciences
GILD
|
+$4.85M |
| 5 |
TSMC
TSM
|
+$4.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.93% |
| 2 | Healthcare | 24.36% |
| 3 | Consumer Discretionary | 11.82% |
| 4 | Communication Services | 11.17% |
| 5 | Consumer Staples | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Nkarta
NKTX
$171M
| $26K | ﹤0.01% |
14,155
-808
| -5% | -$1.66K |
|
452
Alector
ALEC
$240M
| $24.4K | ﹤0.01% |
19,875
-890
| -4% | -$1.45K |
|
453
Enanta Pharmaceuticals
ENTA
$393M
| $23.6K | ﹤0.01% |
4,279
-215
| -5% | -$1.33K |
|
454
Lexeo Therapeutics
LXEO
$382M
| $23K | ﹤0.01% |
6,632
-379
| -5% | -$1.68K |
|
455
C4 Therapeutics
CCCC
$480M
| $22.8K | ﹤0.01% |
14,239
-728
| -5% | -$2.17K |
|
456
Align Technology
ALGN
$12.4B
| $21.1K | ﹤0.01% |
133
| – | – |
|
457
Editas Medicine
EDIT
$436M
| $19.2K | ﹤0.01% |
16,558
-945
| -5% | -$1.39K |
|
458
Edwards Lifesciences
EW
$53.6B
| $18.6K | ﹤0.01% |
256
| – | – |
|
459
Fate Therapeutics
FATE
$317M
| $18.1K | ﹤0.01% |
22,845
-1,305
| -5% | -$1.6K |
|
460
Kyverna Therapeutics
KYTX
$489M
| $16.7K | ﹤0.01% |
8,659
-495
| -5% | -$1.46K |
|
461
Pliant Therapeutics
PLRX
$66.3M
| $16.5K | ﹤0.01% |
12,206
-697
| -5% | -$4.23K |
|
|
CLYM
462
Climb Bio
CLYM
$827M
| $16.4K | ﹤0.01% |
13,484
-770
| -5% | -$1.25K |
|
463
MacroGenics
MGNX
$256M
| $16K | ﹤0.01% |
12,589
-719
| -5% | -$1.88K |
|
464
Biomea Fusion
BMEA
$92.8M
| $15.5K | ﹤0.01% |
7,269
-415
| -5% | -$1.41K |
|
465
Repligen
RGEN
$9.35B
| $14.6K | ﹤0.01% |
115
| – | – |
|
|
ARTV
466
Artiva Biotherapeutics
ARTV
$564M
| $14.6K | ﹤0.01% |
4,872
-278
| -5% | -$1.5K |
|
467
TScan Therapeutics
TCRX
$50.5M
| $13.6K | ﹤0.01% |
9,847
-563
| -5% | -$1.22K |
|
468
Charles River Laboratories
CRL
$13.6B
| $13.4K | ﹤0.01% |
89
| – | – |
|
469
GSK
GSK
$101B
| $13.2K | ﹤0.01% |
338
| – | – |
|
470
Acrivon Therapeutics
ACRV
$73.6M
| $12.7K | ﹤0.01% |
6,245
-357
| -5% | -$1.92K |
|
471
Quanterix
QTRX
$139M
| $12.3K | ﹤0.01% |
1,894
| – | – |
|
|
INZY
472
DELISTED
Inozyme Pharma
INZY
| $11.7K | ﹤0.01% |
12,885
-736
| -5% | -$1.02K |
|
473
Pyxis Oncology
PYXS
$201M
| $11.7K | ﹤0.01% |
11,928
-681
| -5% | -$909 |
|
474
Illumina
ILMN
$29.1B
| $11.6K | ﹤0.01% |
146
-33,629
| -100% | -$3.64M |
|
|
APLT
475
DELISTED
Applied Therapeutics
APLT
| $11.4K | ﹤0.01% |
23,339
-1,333
| -5% | -$785 |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q1 2025 Portfolio in Review
As of Q1 2025, China Universal Asset Management Company held 509 positions worth $1.07B, up 0.55% from $1.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
China Universal Asset Management Company deployed $69.6M of net new capital in Q1 2025, opening 13 new positions and adding to 172 existing holdings. Its largest new stake was VNET Group: 300,000 shares worth $2.46M.
By sector, the portfolio is most concentrated in Technology at 37% of assets, down from 38% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was iShares Silver Trust, an estimated $7.41M trimmed.
- China Universal Asset Management Company's largest Q1 2025 buy was VNET Group: 300,000 shares worth $2.46M.
- China Universal Asset Management Company added most to Apple in Q1 2025, an estimated $12.7M increase.
- China Universal Asset Management Company's biggest Q1 2025 reduction was iShares Silver Trust, cutting an estimated $7.41M.
- China Universal Asset Management Company fully exited Arista Networks in Q1 2025, selling an estimated $6.7M.
- China Universal Asset Management Company's ten largest holdings make up 36% of its $1.07B portfolio in Q1 2025.
- China Universal Asset Management Company opened 13 new positions and closed 23 in Q1 2025.
- China Universal Asset Management Company's portfolio value rose 0.55% quarter-over-quarter to $1.07B.
Based on China Universal Asset Management Company's 13F filing for Q1 2025, filed 30 Apr 2025.